Champions Oncology (CSBR) Reports Q3 Loss of $0.21/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016
March 15, 2016 8:30 AM EDTHACKENSACK, N.J., March 15, 2016 /PRNewswire/ --Â Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2016.
Third Quarter and Recent Business Highlights:
Delivered record core bookings of new contracts to pharma and biotech customers TOS revenue growth of 55% Launched AML product line Reduced cash burn to under $1M for the quarter Initiated sponsored correlative trial of... More